Details of the Drug

General Information of Drug (ID: DMV0MZ3)

Drug Name
FK-962
Synonyms FK-960 analog, Fujisawa
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 263.31
Logarithm of the Partition Coefficient (xlogp) 2.3
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C15H18FNO2
IUPAC Name
N-(4-acetylcyclohexyl)-4-fluorobenzamide
Canonical SMILES
CC(=O)C1CCC(CC1)NC(=O)C2=CC=C(C=C2)F
InChI
InChI=1S/C15H18FNO2/c1-10(18)11-4-8-14(9-5-11)17-15(19)12-2-6-13(16)7-3-12/h2-3,6-7,11,14H,4-5,8-9H2,1H3,(H,17,19)
InChIKey
PYMCWQVGVQEZNO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
56842107
CAS Number
283167-06-6
TTD ID
D0O3TC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor (SSTR) TTOMNR9 NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00087724) A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
2 FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.